

Max Kates

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10444832/publications.pdf>

Version: 2024-02-01

109
papers

2,584
citations

172457

29
h-index

223800

46
g-index

110
all docs

110
docs citations

110
times ranked

3627
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival Following Lobectomy and Limited Resection for the Treatment of Stage I Non-small Cell Lung Cancer ≤ 1 cm in Size. <i>Chest</i> , 2011, 139, 491-496.	0.8	182
2	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. <i>Oncolmmunology</i> , 2016, 5, e1134412.	4.6	135
3	Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. <i>Clinical Cancer Research</i> , 2020, 26, 882-891.	7.0	98
4	Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2020, 203, 902-909.	0.4	90
5	Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 256.e1-256.e6.	1.6	86
6	Morbidity of Urologic Surgical Procedures: An Analysis of Rates, Risk Factors, and Outcomes. <i>Urology</i> , 2015, 85, 552-560.	1.0	83
7	Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 426.e1-426.e12.	1.6	78
8	Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment Failure. <i>Journal of Urology</i> , 2014, 192, 1633-1638.	0.4	74
9	Increased Risk of Overall and Cardiovascular Mortality After Radical Nephrectomy for Renal Cell Carcinoma 2 cm or Less. <i>Journal of Urology</i> , 2011, 186, 1247-1253.	0.4	68
10	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. <i>World Journal of Urology</i> , 2013, 31, 1535-1539.	2.2	61
11	Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 293-303.	0.4	60
12	Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 594-603.	3.4	54
13	Survival After Diagnosis of Localized T1a Kidney Cancer: Current Population-based Practice of Surgery and Nonsurgical Management. <i>Urology</i> , 2014, 83, 126-133.	1.0	52
14	Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery Era. <i>Urology</i> , 2018, 111, 86-91.	1.0	52
15	Predictive biomarkers for drug response in bladder cancer. <i>International Journal of Urology</i> , 2019, 26, 1044-1053.	1.0	50
16	Validation of a Model to Predict Perioperative Mortality from Lung Cancer Resection in the Elderly. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 390-395.	5.6	46
17	Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 68-73.	0.4	46
18	Three-dimensional organoid culture reveals involvement of Wnt/ β -catenin pathway in proliferation of bladder cancer cells. <i>Oncotarget</i> , 2018, 9, 11060-11070.	1.8	46

#	ARTICLE	IF	CITATIONS
19	Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. <i>Journal of Urology</i> , 2016, 195, 337-342.	0.4	43
20	Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6592-6601.	7.0	43
21	Comorbidities and causes of death in the management of localized T1a kidney cancer. <i>International Journal of Urology</i> , 2014, 21, 1086-1092.	1.0	42
22	PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. <i>European Urology</i> , 2017, 71, 145-146.	1.9	40
23	Quantifying Nonindex Hospital Readmissions and Care Fragmentation after Major Urological Oncology Surgeries in a Nationally Representative Sample. <i>Journal of Urology</i> , 2017, 197, 235-240.	0.4	39
24	Causes, Timing, Hospital Costs and Perioperative Outcomes of Index vs Nonindex Hospital Readmissions after Radical Cystectomy: Implications for Regionalization of Care. <i>Journal of Urology</i> , 2017, 197, 296-301.	0.4	39
25	Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 599-612.	3.8	39
26	Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 2693-2699.	1.5	37
27	Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 204.e1-204.e7.	1.6	34
28	Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer. <i>Nature Communications</i> , 2022, 13, 878.	12.8	33
29	Race and sex disparities in the treatment of older patients with T1a renal cell carcinoma: A comorbidity-controlled competing-risks model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 576-583.	1.6	31
30	Balancing cardiovascular (CV) and cancer death among patients with small renal masses: modification by CV risk. <i>BJU International</i> , 2015, 115, 58-64.	2.5	31
31	The effect of race and gender on the surgical management of the small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1794-1799.	1.6	29
32	Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma. <i>Annals of Nuclear Medicine</i> , 2018, 32, 69-74.	2.2	28
33	Tissue-Engineered Urinary Conduits. <i>Current Urology Reports</i> , 2015, 16, 8.	2.2	27
34	Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 531.e15-531.e24.	1.6	27
35	CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. <i>British Journal of Cancer</i> , 2018, 119, 961-970.	6.4	27
36	Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. <i>BJU International</i> , 2015, 115, 216-222.	2.5	25

#	ARTICLE	IF	CITATIONS
37	Predictors of locally advanced and metastatic disease in patients with small renal masses. <i>BJU International</i> , 2012, 109, 1463-1467.	2.5	23
38	M1 Macrophages Are Predominantly Recruited to the Major Pelvic Ganglion of the Rat Following Cavernous Nerve Injury. <i>Journal of Sexual Medicine</i> , 2017, 14, 187-195.	0.6	23
39	Ex Vivo Model of Human Penile Transplantation and Rejection: Implications for Erectile Tissue Physiology. <i>European Urology</i> , 2017, 71, 584-593.	1.9	21
40	Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 34.e17-34.e25.	1.6	21
41	Arsenic promotes the <sc>COX2/PGE2</sc> axis to increase the malignant stemness properties of urothelial cells. <i>International Journal of Cancer</i> , 2018, 143, 113-126.	5.1	21
42	Never Events: Centers for Medicare and Medicaid Services Complications After Radical Cystectomy. <i>Urology</i> , 2013, 81, 527-532.	1.0	19
43	The Financial Impact of Robotic Technology for Partial and Radical Nephrectomy. <i>Journal of Endourology</i> , 2015, 29, 317-322.	2.1	19
44	Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a Difference. <i>Bladder Cancer</i> , 2016, 2, 225-234.	0.4	19
45	Secondary bladder cancer after upper tract urothelial carcinoma in the US population. <i>BJU International</i> , 2012, 110, 1325-1329.	2.5	18
46	Persistent Overuse of Radical Nephrectomy in the Elderly. <i>Urology</i> , 2011, 78, 555-559.	1.0	17
47	Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. <i>Canadian Urological Association Journal</i> , 2016, 10, 389.	0.6	17
48	Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. <i>Cell Reports Medicine</i> , 2021, 2, 100382.	6.5	17
49	Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method. <i>Urology</i> , 2018, 115, 82-86.	1.0	16
50	In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 53.e9-53.e14.	1.6	15
51	Immune checkpoint inhibitors: a new frontier in bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 49-55.	2.2	15
52	Sickle Cell Disease in Priapism: Disparity in Care?. <i>Urology</i> , 2015, 86, 72-79.	1.0	14
53	Accuracy of urethral frozen section during radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 532.e1-532.e6.	1.6	13
54	Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 160.e23-160.e32.	1.6	13

#	ARTICLE	IF	CITATIONS
55	An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 40.e17-40.e24.	1.6	13
56	Use of regenerative tissue for urinary diversion. <i>Current Opinion in Urology</i> , 2015, 25, 578-585.	1.8	12
57	Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. <i>Urology</i> , 2017, 102, 148-158.	1.0	12
58	Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology. <i>World Journal of Urology</i> , 2019, 37, 2051-2058.	2.2	12
59	A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 81, 138-142.	1.9	12
60	Prostate-specific Antigen Mass Density—A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution. <i>Urology</i> , 2016, 90, 141-147.	1.0	11
61	Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 5.e9-5.e16.	1.6	11
62	Renal functional outcomes after surgery for renal cortical tumors. <i>Current Opinion in Urology</i> , 2011, 21, 351-355.	1.8	10
63	Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database. <i>Journal of Sexual Medicine</i> , 2017, 14, 810-817.	0.6	10
64	Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?. <i>BJU International</i> , 2018, 122, 1016-1024.	2.5	10
65	Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 9.e1-9.e7.	1.6	9
66	Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival. <i>Journal of Urology</i> , 2022, 207, 77-85.	0.4	9
67	Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. <i>Journal of Urology</i> , 2022, 207, 61-69.	0.4	9
68	Development and validation of a NanoString BASE47 bladder cancer gene classifier. <i>PLoS ONE</i> , 2020, 15, e0243935.	2.5	9
69	BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. <i>Journal of Pathology</i> , 2022, 256, 223-234.	4.5	9
70	Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 38.e17-38.e24.	1.6	8
71	Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 2683-2689.	2.2	8
72	Dynamic Contrast Enhanced-MR CEST Urography: An Emerging Tool in the Diagnosis and Management of Upper Urinary Tract Obstruction. <i>Tomography</i> , 2021, 7, 80-94.	1.8	8

#	ARTICLE	IF	CITATIONS
73	Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database. <i>BJU International</i> , 2017, 120, 377-386.	2.5	7
74	Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive Factors. <i>Journal of Sexual Medicine</i> , 2017, 14, 1059-1065.	0.6	7
75	Evaluation of Incisional Negative Pressure Wound Therapy in the Prevention of Surgical Site Occurrences After Radical Cystectomy: A New Addition to Enhanced Recovery After Surgery Protocol. <i>European Urology Focus</i> , 2020, 6, 698-703.	3.1	7
76	Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines. <i>Oncology Letters</i> , 2019, 18, 4923-4929.	1.8	7
77	Stones in the Elderly. <i>Current Geriatrics Reports</i> , 2014, 3, 14-18.	1.1	6
78	Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical. <i>Human Pathology</i> , 2019, 90, 1-7.	2.0	6
79	Adjuvant Therapy for Urothelial and Renal Cell Carcinoma. <i>European Urology Focus</i> , 2020, 6, 3-6.	3.1	6
80	Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 60-68.	1.9	6
81	Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 195.e13-195.e18.	1.6	6
82	Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 117-120.	5.4	5
83	Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 127-135.	1.2	5
84	Indeterminate atypia in urinary tract cytology: Does it really matter?. <i>Diagnostic Cytopathology</i> , 2022, 50, 176-183.	1.0	5
85	High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 191-199.	0.4	4
86	Oncological outcomes of intravesical gemcitabine and docetaxel for select patients with high grade recurrent NMIBC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4546-4546.	1.6	4
87	Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. <i>Journal of Urology</i> , 2022, 207, 534-540.	0.4	4
88	Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022, 208, 821-829.	0.4	4
89	Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor. <i>World Journal of Urology</i> , 2020, 38, 389-395.	2.2	3
90	Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2085-2095.	5.8	3

#	ARTICLE	IF	CITATIONS
91	A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models. <i>Journal of Urology</i> , 2020, 203, 546-553.	0.4	3
92	Plastic exposure and urological malignancies – an emerging field. <i>Nature Reviews Urology</i> , 2020, 17, 653-654.	3.8	2
93	Immunotherapy for Prostate Cancer – Why Now?. <i>Urology Practice</i> , 2017, 4, 329-334.	0.5	1
94	Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4623-4623.	1.6	1
95	Prediction of Perioperative Mortality after Lung Cancer Resection in the Elderly. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 794-795.	5.6	0
96	Reply. <i>Urology</i> , 2015, 86, 78-79.	1.0	0
97	Author Reply. <i>Urology</i> , 2017, 102, 158.	1.0	0
98	Open Versus Robot-assisted Radical Cystectomy: Is Standardization Without Randomization Possible?. <i>European Urology</i> , 2021, 79, 619-620.	1.9	0
99	Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Letter.. <i>Journal of Urology</i> , 2021, , 101097JU00000000000002306.	0.4	0
100	Effect of chemotherapy and/or TURBT on pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 395-395.	1.6	0
101	Examining gemcitabine and docetaxel for recurrent NMIBC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 322-322.	1.6	0
102	Incidence of T3a upstaging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4588-4588.	1.6	0
103	2542. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 83-83.	0.6	0
104	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 1011-1012.	0.4	0
105	Validation of an artificial intelligence algorithm applied to a metabolic substrate analysis of urine for detection of urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16008-e16008.	1.6	0
106	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 769-769.	0.4	0
107	Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 525-525.	1.6	0
108	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 552-553.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0